Illumina reagents and consumables
Ended Awarded Last action
- Contract number
- 75N91026F00001
- Awardee
-
Illumina, Inc. UEI KMW3CRWNAAF3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $250,256
Award facts
- Contract value 100% obligated
- $250,256.07 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- 6640 Laboratory Equipment And Supplies
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92122, USA
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute awarded a delivery order to Illumina, Inc. for Illumina reagents and consumables with a ceiling value of $250,256.07 under a firm fixed-price contract structure. The award was issued on February 26, 2026, with an ultimate completion date of March 31, 2026. This delivery order does not utilize a set-aside designation and will be performed in San Diego, California, where Illumina maintains its headquarters. The contract supports the National Cancer Institute's genomic research and cancer diagnostics initiatives by providing essential laboratory consumables and reagent kits from the industry-leading sequencing technology provider.
Illumina, Inc. is a specialized biotechnology manufacturer that serves as a prime contractor across multiple federal agencies, supplying next-generation DNA and RNA sequencing systems, reagents, consumables, and bioinformatics software. The company maintains substantial federal contracting relationships, most notably a $45 million indefinite delivery contract with the U.S. Department of Agriculture effective through June 2030, along with task orders and delivery orders issued by the National Institutes of Health, Department of Veterans Affairs, Defense Health Agency, Food and Drug Administration, and other civilian agencies. Illumina's positioned as a foundational technology provider for contemporary genomic research, and this National Cancer Institute delivery order reflects the agency's reliance on the company's specialized sequencing consumables to support cancer research and diagnostic capabilities.
Quick answers
Who was awarded contract 75N91026F00001?
75N91026F00001 was awarded to Illumina, Inc. by National Cancer Institute (National Institutes of Health) on February 26, 2026.
How much is contract 75N91026F00001 worth?
The government has obligated $250,256 on 75N91026F00001.
Is contract 75N91026F00001 an order under another contract?
Yes. 75N91026F00001 is a delivery order under 75N92020D00022, an indefinite delivery contract.
Was contract 75N91026F00001 competed?
The extent of competition for 75N91026F00001 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award